Abstracts tagged "axial spondyloarthritis"

Abstract Number: 2025 • 2015 ACR/ARHP Annual Meeting
Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial
Walter Maksymowych¹, Stephanie Wichuk², Maxime Dougados³, Heather Jones⁴, Annette Szumski⁵, Lisa Marshall⁴, Jack F Bukowski⁶ and Robert G Lambert⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology Research Lab, University of Alberta, Edmonton, AB, Canada, ³Rheumatology Department, Hôpital Cochin, Paris, France, ⁴Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Modification of structural lesions by anti-TNF therapy has not been demonstrated in a randomized placebo (PBO)-controlled trial. The Spondyloarthritis Research Consortium of Canada (SPARCC)…
Abstract Number: 2298 • 2015 ACR/ARHP Annual Meeting
Misdiagnosis of Fibromyalgia (FM) As Axial Spondylarthritis (SpA): Lessons from Analysis of 26 Cases
Dongfeng Liang, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: Both patients with fibromyalgia (FM) and with axial spondyloarthritis (SpA) are suffering from pain. The patients with axial SpA are mainly manifested as inflammatory…
Abstract Number: 2629 • 2015 ACR/ARHP Annual Meeting
The Most Frequent Fears and Beliefs of 226 Patients with Rheumatoid Arthritis or Spondyloarthritis, Using a Novel Questionnaire
Laure Gossec^1,2, Pierre Chauvin^3,4, Christophe Hudry⁵, Florence Mathoret-Philibert⁶, Maud Poussière⁷, Thibault de Chalus⁸, Francoise Russo-Marie⁹, Jean-Michel Joubert⁸, Alain Saraux¹⁰ and Francis Berenbaum^1,11, ¹Rheumatology Department, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ²Rheumatology Department, AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³Department of Social Epidemiology, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ⁴Department of Social Epidemiology, Pierre Louis Institute of Epidemiology and Public Health, Paris, France, ⁵Rheumatology, AP-HP, Hôpital Cochin, Paris, France, ⁶Clinical Psychology Department, AP-HP, Hôpital Cochin, Paris, France, ⁷Independent Researcher, Paris, France, ⁸UCB Pharma, Colombes, France, ⁹Arthritis Foundation Courtin, Neuilly-sur-Seine, France, ¹⁰Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹¹Rheumatology Department, AP-HP, Hôpital Saint-Antoine, Paris, France
Background/Purpose: Patients with chronic inflammatory disorders such as rheumatoid arthritis (RA) or spondyloarthritis (SpA) create personal sets of fears and beliefs related to their disease.…
Abstract Number: 2632 • 2015 ACR/ARHP Annual Meeting
Development and Validation of a Questionnaire Assessing the Fears and Beliefs of Patients Suffering from Chronic Rheumatic Diseases
Laure Gossec^1,2, Alain Saraux³, Christophe Hudry⁴, Florence Mathoret-Philibert⁵, Maud Poussière⁶, Thibault de Chalus⁷, Francoise Russo-Marie⁸, Jean-Michel Joubert⁷, Pierre Chauvin⁹ and Francis Berenbaum^1,10, ¹Rheumatology Department, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ²Rheumatology Department, AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁴Rheumatology, AP-HP, Hôpital Cochin, Paris, France, ⁵Clinical Psychology Department, AP-HP, Hôpital Cochin, Paris, France, ⁶Independent Researcher, Paris, France, ⁷UCB Pharma, Colombes, France, ⁸Arthritis Foundation Courtin, Neuilly-sur-Seine, France, ⁹Department of Social Epidemiology, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ¹⁰Rheumatology Department, Hôpital Saint-Antoine, Paris, France
Background/Purpose: Questionnaires assessing the beliefs of patients with chronic rheumatic diseases mainly focus on medications.1A validated questionnaire evaluating patients' fears and beliefs towards their disease…
Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Sizheng Zhao^1,2, Barbara Hauser³, Micaela Visconti³, Philip L. Riches³, Stuart H. Ralston³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ³Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
Abstract Number: 2812 • 2015 ACR/ARHP Annual Meeting
Cytokine Secretion By Peripheral Blood Mononuclear Cells in Patients with Axial Spondyloarthritis and the Effect of Thymoquinone on Cytokine Profile
Erkan Kilic¹, Cagri Sakalar², Huriye Aksu³, Mustafa Cakir³, Gamze Kilic¹ and Salih Ozgocmen⁴, ¹Dept. PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey, ²Genome and Stem Cell Center (GEN-KOK), Erciyes University, Faculty of Medicine, Medical Biology, Kayseri, Turkey, ³Genome and Stem Cell Senter (GEN-KOK), Erciyes University, Faculty of Medicine, Medical Biology, Kayseri, Turkey, ⁴Dept.PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) defines a group of chronic inflammatory diseases which includes non-radiographic axSpA (nr-axSpA) who do not have definite sacroiliitis on pelvic X-rays.…
Abstract Number: 663 • 2015 ACR/ARHP Annual Meeting
Mases Correlates Linearly with Disease Activity and Patient Related Outcomes in Patients with Axial Spondyloarthritis within the Scqm Cohort
Ruediger Mueller¹, Toni Kaegi², Nicole Graf³, Johannes von Kempis⁴ and J.J. Luime⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³graf biostatistics, Winterthur, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…
Abstract Number: 2876 • 2015 ACR/ARHP Annual Meeting
Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Maxime Dougados¹, Gina Bergman², Walter Maksymowych³, Sean P. Curtis², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Paris-Descartes University, Paris, France, ²Merck & Co., Inc., Kenilworth, NJ, ³University of Alberta, Edmonton, AB, Canada, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Subgroup analyses can be used to investigate the size and direction of treatment effects across a range of demographic and disease characteristics. The purpose…
Abstract Number: 1573 • 2014 ACR/ARHP Annual Meeting
Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients
Brigitte Michelsen¹, Andreas P. Diamantopoulos², Arthur Kavanaugh³ and Glenn Haugeberg^1,4, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³University of California San Diego, La Jolla, CA, ⁴Faculty of Health and Sport Sciences, University of Agder, Kristiansand, Norway
Background/Purpose Higher rates of obesity in psoriatic arthritis (PsA) compared to rheumatoid arthritis (RA) have been described. Obesity, C-reactive protein (CRP) and inflammatory arthritides itself…
Abstract Number: 1581 • 2014 ACR/ARHP Annual Meeting
Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies
Majed Khraishi¹, Heather Jones^2,3 and Annette Szumski⁴, ¹Clinical Professor of Medicine (Rheumatology), Memorial University of Newfoundland, St. John's, NF, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) may have clinical features suggestive of axial skeletal abnormalities and should be assessed for the presence…
Abstract Number: 855 • 2014 ACR/ARHP Annual Meeting
Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Etanercept
Walter P. Maksymowych¹, S Wichuk¹, H Jones², A Szumski³, L Marshall⁴, J Bukowski⁵ and RG Lambert⁶, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Previous studies evaluating predictors of major clinical response in patients with non-radiographic axial SpA (nr-axSpA) receiving treatment with anti-TNF agents have been limited by…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…
Abstract Number: 2938 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
J Sieper¹, D van der Heijde², M Dougados³, Walter P. Maksymowych⁴, J Boice⁵, G Bergman⁵, S Curtis⁵, A Tzontcheva⁵, S Huyck⁵ and HH Weng⁵, ¹University Clinic Benjamin Franklin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Paris-Descartes University, Paris, France, ⁴Department of Medicine, University of Alberta, Alberta, AK, ⁵Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose Axial spondyloarthritis (axSpA), including ankylosing spondylitis and nonradiographic axial SpA (nr-axSpA), is a chronic inflammatory disease marked by back pain and progressive spinal stiffness.…
Abstract Number: 589 • 2014 ACR/ARHP Annual Meeting
Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa
Lennart TH Jacobsson¹, Tomas Husmark², Elke Theander³, Kenneth Henriksson⁴, Katharina Büsch⁵ and Martin Johansson⁵, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴Rheumatology city clinic, Stockholm, Sweden, Stockholm, Sweden, ⁵AbbVie AB, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose The ASAS axial SpA classification criteria was published in 2009 but so far there has been limited research on axial SpA patients in clinical…
Abstract Number: 2604 • 2014 ACR/ARHP Annual Meeting
Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis : the Same Syndrome or Different Diseases? Analysis from Esperanza Cohort
Azucena Hernández-Sanz¹, Victoria Navarro-Compán², Cristina Fernández-Carballido³, Carlos Montilla-Morales⁴, Juan Mulero⁵ and Eugenio De Miguel⁶, ¹H. Virgen de la Salud, Toledo, Spain, ²Rheumatology, University Hospital La Paz, Madrid, Spain, ³Rheumatology, University General Hospital Elda, Elda (Alicante), Spain, ⁴H. de Salamanca, Salamanca, Spain, ⁵Rheumatology, University Hospital Puerta de Hierro, Majadahonda (Madrid), Spain, ⁶Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose New ASAS criteria for axial spondyloarthritis (axSpA) have two entrances: the imaging and clinical arm (presence of HLA B27). The imaging arm allows classifying patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].